Inside Soligenix: Innovations in Rare Disease Therapies

8 months ago
1
Soligenix biopharmaceutical rare disease treatments Specialized BioTherapeutics HyBryte™ for CTCL Phase 3 study HyBryte™ marketing approval synthetic hypericin (SGX302) for psoriasis oral beclomethasone 17 21-dipropionate (BDP) for GI disorders dusquetide (SGX942) for inflammatory diseases

Soligenix, a leading biopharmaceutical company, has a promising pipeline of breakthrough treatments, including HyBryte™ for cutaneous T-cell lymphoma. This innovative therapy, with positive Phase 3 results published in JAMA Dermatology, targets a global market worth $250 million, addressing a critical medical need. Soligenix is on the cusp of major success with the potential for over $2 billion in annual sales. Learn more at https://www.redchip.com/stocks/SNGX/.

Loading comments...